SCHEDULE: Nantahala Capital Management Discloses 14.5% Stake in TELA Bio

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 6,545,596 shares, representing 14.5% of TELA Bio, Inc.'s common stock as of September 30, 2026.

Summary

• Nantahala Capital Management, LLC, and its managing members Wilmot B. Harkey and Daniel Mack, have filed a Schedule 13G, indicating their beneficial ownership of TELA Bio, Inc. common stock.
• As of September 30, 2026, the reporting persons collectively beneficially own 6,545,596 shares of TELA Bio, Inc. common stock.
• This ownership stake represents 14.5% of the total outstanding shares of the company's common stock.
• Nantahala Capital Management, LLC is identified as an investment adviser, and Messrs. Harkey and Mack are identified as control persons.
• Blackwell Partners LLC - Series A, a fund advised by Nantahala, has the right to receive dividends or direct the sale of more than five percent of the shares beneficially owned by Nantahala.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but stable ownership stake without immediate aggressive action.

Positives

• Significant ownership stake (14.5%) by Nantahala Capital Management, LLC, suggesting strong conviction in TELA Bio, Inc.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing control.
• Blackwell Partners LLC - Series A, a fund advised by Nantahala, has rights to dividends and sale proceeds, indicating a structured investment approach.

Negatives

• The filing does not provide specific details on the acquisition cost or strategy behind the significant stake.
• No forward-looking statements or explicit strategic intentions beyond ordinary course of business are detailed.

Risks

• Potential for increased scrutiny from the market regarding Nantahala's intentions, even if not aimed at control.
• Dependence on the performance of TELA Bio, Inc. for the investment's success.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. The reporting persons certify that the securities were acquired and are held in the ordinary course of business.

Management Comments

• "Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E)."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive or long-term investment stakes. Nantahala Capital Management's significant holding in TELA Bio, Inc. places them as a major shareholder, which could influence future corporate actions or strategic discussions, though the filing explicitly states no intent to influence control.

Related Party Transactions

• Blackwell Partners LLC - Series A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than five percent of the outstanding shares of common stock beneficially owned by Nantahala.

Stakeholder Impact

• Shareholders: The significant stake may signal confidence to other investors, potentially impacting share price, but also raises questions about future strategic direction.
• Management: May face increased engagement or dialogue with Nantahala Capital Management regarding company strategy and performance.
• Fund Investors (e.g., Blackwell Partners LLC - Series A): Benefit from the investment performance of TELA Bio, Inc. through Nantahala's management.

Next Steps

• Monitor future filings from Nantahala Capital Management, LLC for any changes in their ownership stake.
• Observe TELA Bio, Inc.'s strategic decisions and performance, which may be influenced by significant shareholders like Nantahala.

Key Dates

Recommendation

The filing indicates a substantial, but not controlling, stake acquired in the ordinary course of business. While it signals confidence from Nantahala Capital Management, there's no indication of an activist strategy or immediate catalyst for a significant price movement. Therefore, a 'hold' recommendation is appropriate pending further developments or strategic shifts.

Keywords

TELA Bio, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, Wilmot B. Harkey, Daniel Mack